MedPath

Vantis Vascular's CrossFAST Guide Extension System Receives FDA Clearance

• Vantis Vascular has received FDA 510(k) clearance for its CrossFAST Integrated Microcatheter Guide Extension System, designed for complex coronary and peripheral interventions. • The CrossFAST system utilizes patented DuoPro Interlocking Technology to enhance deliverability and safety in challenging anatomies, potentially improving patient outcomes. • Expected to be commercially available in the United States in Q4 2024 with a limited market release, followed by a full market release planned for 2025. • The system addresses the need for improved guide extension catheters in complex, high-risk patients, offering smoother navigation to target locations.

Vantis Vascular, Inc., a medical technology company focused on vascular interventions, announced FDA 510(k) clearance for its CrossFAST Integrated Microcatheter Guide Extension System. This system is designed to aid physicians in performing faster, easier, and safer procedures for complex coronary and peripheral interventions.
The CrossFAST system aims to improve navigation in complex, calcified, and tortuous anatomies. According to Tim Fischell, MD, Chief Medical Officer at Vantis, there is a significant need to improve existing guide extension catheters due to anatomical challenges and the increasing prevalence of complex high-risk patients. The CrossFAST System is designed for smooth and effortless deliverability, potentially revolutionizing access to target locations.

Technology and Design

Guide extension catheters are crucial in vascular interventions, providing support and facilitating device delivery in challenging anatomies. Traditional catheters often lack sufficient pushability and can risk vessel trauma during delivery. The CrossFAST Guide Extension System addresses these limitations with its patented DuoPro Interlocking Technology, a mechanism that couples the outer and inner extension catheters. This design enhances safety and deliverability, improving interventional procedures from start to finish.

Company Statement

Jason Turner, Chief Executive Officer at Vantis, stated that the FDA clearance marks a significant milestone in the company's mission to transform how physicians navigate complex and calcific anatomy. He added that the CrossFAST System reflects their commitment to addressing the real challenges physicians face in complex interventions, ultimately enabling better patient outcomes.

Market Availability

The CrossFAST Guide Extension System will be commercially available in the United States in Q4 2024 as part of a limited market release, with a full market release planned for 2025.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Merit Medical's WRAPSODY Endoprosthesis Receives FDA Approval for Dialysis Patients

Merit Medical's WRAPSODY Cell-Impermeable Endoprosthesis receives FDA premarket approval, paving the way for its commercial launch in the U.S. in 2025.
The WRAPSODY device is designed to extend long-term vessel patency in dialysis patients by addressing stenosis and thrombosis in arteriovenous (AV) fistulas and grafts.

Centerline Biomedical's IOPS Guidewire Handle Receives FDA 510(k) Clearance

Centerline Biomedical's IOPS Guidewire Handle, a second-generation device, has received FDA 510(k) clearance, enhancing its IOPS technology portfolio.
The IOPS Guidewire Handle, used with a sensorized guidewire and viewpoint catheter, supports real-time 3D navigation of vasculature.

MVITRO's ORTIV Receives FDA Clearance for Needle-Free Blood Sampling

MVITRO's ORTIV, a laser-based device for painless blood sampling and glucose monitoring, has secured FDA 510(k) clearance, marking a significant advancement in diabetes management.
ORTIV utilizes micro-lasers to minimize skin damage and eliminate infection risks, offering real-time glucose readings via a dedicated app, addressing the stress of traditional blood sampling.

Vantis Vascular's CrossFAST Guide Extension System Receives FDA Clearance for Complex Vascular Interventions

Vantis Vascular's CrossFAST Integrated Microcatheter Guide Extension System has received FDA 510(k) clearance, designed to improve the speed and safety of vascular procedures.
The CrossFAST system utilizes patented DuoPro Interlocking Technology to enhance deliverability in complex, calcified, and tortuous anatomies, addressing limitations of traditional guide extension catheters.

FDA Clears Gentuity's HF-OCT Imaging System for Coronary Interventions

Gentuity receives FDA 510(k) clearance for its HF-OCT imaging system with the Vis-Rx micro-imaging catheter, enhancing coronary intervention procedures.
The system is the only intravascular imaging platform indicated for pre- and post- percutaneous coronary intervention (PCI) assessment, optimizing treatment plans.

FDA Clears Pi-Cardia's ShortCut Device for Valve-in-Valve TAVR Procedures

Pi-Cardia's ShortCut device receives FDA clearance to reduce coronary obstruction risk during valve-in-valve transcatheter aortic valve replacement (TAVR).
The ShortCut device mechanically splits aortic valve leaflets before valve placement, differing from electrosurgery-based methods like the BASILICA procedure.

B. Braun's Introcan Safety 2 Deep Access IV Catheter Receives FDA Clearance

B. Braun Medical's Introcan Safety 2 Deep Access IV Catheter has received FDA 510(k) clearance, expanding the Introcan Safety 2 portfolio.
The catheter combines features of the original Introcan Safety 2 Multi-Access and Deep Access catheters for enhanced vascular access.

FDA Approves Biotronik's Left Bundle Branch Area Pacing System

The FDA has granted approval for Biotronik's Selectra 3D catheter and Solia S lead system for left bundle branch area pacing (LBBAP).
The approval was based on the BIO-CONDUCT trial, which demonstrated a 95.7% implant success rate and a low 1.7% lead-related complication rate.

FDA Accepts Vertex's NDA for Next-Gen Cystic Fibrosis Triple Therapy

The FDA has accepted Vertex's NDA for vanzacaftor/tezacaftor/deutivacaftor, a triple combination therapy for cystic fibrosis (CF) patients aged 6 and older.
This therapy targets those with at least one _F508del_ mutation or another mutation responsive to the drug in the _CFTR_ gene.

Innovations and Trials in Medical Technology

Recent advancements in medical technology include the launch of the CrossWise RF transseptal access system by Circa Scientific, completion of enrollment in a pivotal trial for Inquis Medical's Aventus thrombectomy system, a distribution agreement between Medtronic and Contego Medical, a $12 million Series A round for Relief Cardiovascular, CE mark approval for Johnson & Johnson MedTech's dual-energy catheter, a temporary pause on Varipulse PFA system cases by Johnson & Johnson MedTech, and the completion of a first-in-human study by AerWave for its lung denervation therapy.

Reference News

[1]
VANTIS VASCULAR RECEIVES FDA CLEARANCE FOR ITS CROSSFAST™ GUIDE ...
prnewswire.com · Oct 25, 2024

Vantis Vascular announces FDA 510(k) clearance for CrossFAST Integrated Microcatheter Guide Extension System, designed f...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy